Crawford S W
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
West J Med. 1991 Nov;155(5):488-93.
Hematologic neoplasms that were previously considered fatal are now potentially curable with techniques such as bone marrow transplantation. Such therapies also carry significant morbidity and mortality. With the increasing application of these therapies, a growing number of physicians are using medical decision making regarding critical care for these patients. The process by which ethical decisions are reached for these critically ill patients may be baffling because of several factors: rapidly evolving treatments, uncertain probabilities of the cure of the malignant disorder, the relatively young age of many of these patients, and the poor prognosis with critical illness. I discuss a process to reach acceptable decisions, providing a case example of the application of the process. This process is derived from the ethical principles that drive decision making in general medicine and attempts to maximize patients' autonomy. It involves a consideration of accurate information regarding the disease process and the prognosis, a clear delineation of the goals of the medical care, and communication with patients. Appropriate, ethical, and consistent decisions regarding the critical care of patients with hematologic malignancy can be reached when these considerations are addressed.
以前被认为是致命的血液系统肿瘤,现在通过骨髓移植等技术有可能治愈。这类疗法也伴有显著的发病率和死亡率。随着这些疗法应用的增加,越来越多的医生在对这些患者进行重症监护时运用医疗决策。由于几个因素,为这些重症患者做出伦理决策的过程可能令人困惑:治疗方法迅速演变、恶性疾病治愈的概率不确定、这些患者中许多人相对年轻以及重症的预后较差。我讨论了一个达成可接受决策的过程,并提供了该过程应用的一个案例。这个过程源自推动普通医学决策的伦理原则,并试图最大限度地提高患者的自主权。它涉及对有关疾病过程和预后的准确信息的考虑、对医疗护理目标的清晰界定以及与患者的沟通。当解决了这些考虑因素时,就可以就血液系统恶性肿瘤患者的重症监护做出适当、符合伦理且一致的决策。